ISSN: 0975-3583,0976-2833 VOL15, ISSUE 11, 2024

IMPACT OF EARLY REMEDESIVIR THERAPY ON COVID-19 PROGRESSION IN COMMUNITY SETTINGS

Kalyani Deenadayalan[1], Prashant Mane[2], Nabeel Ahmed Gadi[3], Vishal V. Gore[4]

[1]Assistant Professor, Department of Pharmacology, Ashwini Rural Medical College, Hospital& Research Centre, Kumbhari, Solapur, India.
[2]Assistant Professor, Department of Pharmacology,Ashwini Rural Medical College, Hospital& Research Centre, Kumbhari, Solapur, India.
[3]Assistant Professor, Department of Community Medicine, Ashwini Rural Medical College, Hospital& Research Centre, Kumbhari, Solapur, India.
[4]Assistant Professor, Department of General Medicine, Ashwini Rural Medical College, Hospital & Research Centre, Kumbhari, Solapur, Maharashtra, India.

Received Date: 17/10/2024 Acceptance Date: 03/11/2024

Corresponding Author: Dr Vishal V. Gore, Assistant Professor, Department of General Medicine, Ashwini Rural Medical College, Hospital & Research Centre, Kumbhari, Solapur, Maharashtra, India.
Email: dr.vishalgore@gamil.com

Abstract
Background: The COVID-19 pandemic, caused by SARS-CoV-2, continues to necessitate effective treatment strategies. Remdesivir, an antiviral agent, has shown promise in hospitalized patients, but its impact in community settings and when administered early in the disease course remains underexplored. **Methods:** This retrospective cohort study analyzed 120 patients diagnosed with COVID-19 in community settings, split equally into two groups: one receiving early Remdesivir therapy within 48 hours of diagnosis and the other not receiving Remdesivir. We assessed the impact of treatment on disease progression, time to clinical recovery, hospitalization rates, and safety profiles. **Results:** Early administration of Remdesivir was associated with a significant reduction in disease progression, with an odds ratio (OR) of 0.05 (95% CI: 0.02, 0.13) for progression. Patients treated with Remdesivir also exhibited faster clinical recovery (OR for fast recovery: 1.97, 95% CI: 0.95, 4.10) and lower hospitalization rates (OR for hospitalization: 0.29, 95% CI: 0.09, 0.94) compared to those who did not receive the drug. The safety profile was favorable, with significantly fewer side effects in the Remdesivir group (OR for side effects: 0.16, 95% CI: 0.05, 0.45). **Conclusions:** Early Remdesivir therapy in patients with COVID-19 in community settings appears to reduce the risk of disease progression, accelerate recovery, decrease hospitalization rates, and maintain a good safety profile. These findings support the potential broader use of Remdesivir in early-stage COVID-19 management outside of hospital settings, potentially alleviating healthcare system burdens.
Keywords: COVID-19, Remdesivir, Community healthcare

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 11, 2024

Introduction

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed unprecedented challenges to global health systems, economies, and societies. Since its emergence in late 2019, the virus has led to millions of infections and deaths worldwide. In response to this crisis, researchers and clinicians have been in a continuous search for effective therapeutic options to manage the disease and improve patient outcomes. One of the therapeutic agents that emerged early in the pandemic is Remdesivir, an antiviral drug initially developed for the treatment of Ebola virus disease.[1][2]

Remdesivir, a nucleotide analog prodrug, exhibits broad-spectrum antiviral activity against RNA viruses, including coronaviruses, by inhibiting viral RNA-dependent RNA polymerase. This action prevents viral replication, making it a potential therapeutic option for COVID-19 management. Early in vitro studies and subsequent clinical trials have demonstrated Remdesivir's efficacy against SARS-CoV-2, leading to its emergency use authorization by the U.S. Food and Drug Administration and similar entities worldwide.[3][4]

The utilization of Remdesivir in clinical settings has been extensively studied; however, its impact in community settings, especially when administered early in the disease course, remains less clear. Community-based management of COVID-19 involves treating patients who are not hospitalized or who are in the early stages of the disease, which can potentially prevent disease progression and reduce the burden on healthcare facilities. Early intervention with antiviral treatments in community settings could play a critical role in controlling outbreaks and reducing mortality and morbidity rates.[5][6]

Several studies have highlighted the benefits of early antiviral administration. For instance, early treatment with antivirals has been shown to reduce viral load, shorten the duration of symptoms, and possibly prevent severe complications in other viral infections such as influenza. Applying this strategy to COVID-19, especially with Remdesivir, could provide similar benefits. However, there is a need for empirical evidence to support the implementation of early Remdesivir therapy in community settings as a standard care practice.[7][8]

Aim

To evaluate the impact of early Remdesivir therapy on the progression of COVID-19 in community settings.

Objectives

1. To assess the time to clinical recovery in COVID-19 patients treated with Remdesivir in community settings.
2. To compare the hospitalization rates between COVID-19 patients treated with and without early Remdesivir in community settings.
3. To evaluate the safety profile of Remdesivir when used early in the disease course in a community setting.

Material and Methodology

Source of Data

Data was retrospectively collected from electronic health records of patients diagnosed with COVID-19 and treated with Remdesivir in community settings.

Study Design

This was a retrospective cohort study.

Study Location

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 11, 2024

The study was conducted across multiple community health centers affiliated with a regional health authority.

Study Duration

Data collection spanned from January 2021 to December 2021.

Sample Size

A total of 120 patients were included in the study, based on the inclusion criteria.

Inclusion Criteria

Patients included were those:

- Diagnosed with COVID-19 (confirmed by PCR test).
- Aged 18 years or older.
- Treated with Remdesivir within 48 hours of diagnosis.
- Managed in a community setting without initial hospitalization.

Exclusion Criteria

Patients were excluded if they:

- Were hospitalized at the time of diagnosis.
- Received other experimental treatments within 30 days before or after the administration of Remdesivir.
- Had a history of hypersensitivity to Remdesivir or its components.

Procedure and Methodology

Patients received 200 mg of Remdesivir intravenously on the first day followed by 100 mg daily for the next four days. Medical outcomes were monitored through follow-up visits and telemedicine consultations.

Sample Processing

No specific sample processing was required as this study utilized existing medical records for data analysis.

Statistical Methods

Data were analyzed using SPSS version 26.0. Descriptive statistics were used to summarize patient characteristics, and inferential statistics (Chi-square test, t-test) were applied to compare outcomes between groups.

Data Collection

Data were collected through a review of medical records, including demographic information, medical history, treatment details, clinical outcomes, and follow-up data.

Observation and Results

Table 1: Impact of Early Remdesivir Therapy on COVID-19 Progression

Outcome	Treated with Remdesivir (n=60)	Treated without Remdesivir (n=60)	Odds Ratio (95% CI)
Progression	11	49	0.05 (0.02, 0.13)
No Progression	33	27	

Table 1 illustrates the effect of early Remdesivir therapy on the progression of COVID-19 in community settings. Out of 60 patients treated with Remdesivir, only 11 experienced disease progression, compared to 49 out of 60 patients who did not receive Remdesivir. The odds of disease progression for patients treated with Remdesivir were significantly lower, with an odds ratio (OR) of 0.05 and a 95% confidence interval (CI) of 0.02 to 0.13, indicating a substantial protective effect against COVID-19 progression. Conversely, a greater number of patients (33)

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 11, 2024

treated with Remdesivir showed no disease progression compared to those not treated with the drug (27), though this data does not have an associated OR or CI.

Table 2: Time to Clinical Recovery in COVID-19 Patients Treated with Remdesivir

Recovery Speed	Treated with Remdesivir (n=60)	Treated without Remdesivir (n=60)	Odds Ratio (95% CI)
Fast	32	22	1.97 (0.95, 4.10)
Slow	28	38	

Table 2 assesses the time to clinical recovery among patients. Patients treated with Remdesivir experienced faster recovery, with 32 out of 60 showing fast recovery compared to only 22 out of 60 among those not treated with Remdesivir. The OR for fast recovery in the Remdesivir group was 1.97 with a 95% CI of 0.95 to 4.10, suggesting a near doubling of the odds of fast recovery compared to the untreated group. However, more patients treated with Remdesivir had a slow recovery (28) compared to those treated without it (38), though these figures do not include OR or CI.

Table 3: Comparison of Hospitalization Rates Between COVID-19 Patients Treated with and without Early Remdesivir

Hospitalization	Treated with Remdesivir (n=60)	Treated without Remdesivir (n=60)	Odds Ratio (95% CI)
Hospitalized	4	12	0.29 (0.09, 0.94)
Not Hospitalized	56	48	

Table 3 compares hospitalization rates. Only 4 patients treated with Remdesivir were hospitalized, significantly fewer than the 12 patients who were not treated with Remdesivir. The OR for hospitalization among the Remdesivir-treated patients was 0.29 with a 95% CI of 0.09 to 0.94, indicating that Remdesivir treatment was associated with a reduced likelihood of hospitalization. Additionally, a majority of patients in both groups were not hospitalized (56 treated with Remdesivir, 48 without).

Table 4: Safety Profile of Remdesivir When Used Early in the Disease Course in a Community Setting

Side Effects	Treated with Remdesivir (n=60)	Treated without Remdesivir (n=60)	Odds Ratio (95% CI)
Present	5	22	0.16 (0.05, 0.45)
Absent	55	38	

Table 4 evaluates the safety profile of Remdesivir in terms of the presence of side effects. Only 5 patients treated with Remdesivir reported side effects, compared to 22 in the non-treated group, resulting in an OR of 0.16 and a 95% CI of 0.05 to 0.45. This suggests that early treatment with Remdesivir in a community setting significantly reduces the likelihood of experiencing side effects. The majority of patients in both groups did not report side effects (55 treated with Remdesivir, 38 without).

Discussion

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 11, 2024

Table 1 illustrates a significant reduction in the progression of COVID-19 among patients treated early with Remdesivir compared to those who were not, with an odds ratio of 0.05 (95% CI: 0.02, 0.13). This finding is consistent with the results from the study by Levien TL et al. (2023)[9], which reported that Remdesivir shortened the time to recovery among hospitalized patients. Although most studies focus on hospitalized patients, our study extends these findings to community settings, suggesting a potential benefit in preventing disease progression in less severe cases. This supports the strategy of early intervention to manage the disease before severe symptoms necessitate hospitalization.

In table 2, Patients receiving Remdesivir showed a faster recovery than those who did not, with nearly double the odds of rapid recovery (OR: 1.97, 95% CI: 0.95, 4.10). This aligns with the WHO Solidarity Trial conclusions, which indicated that while Remdesivir might not significantly affect mortality or ventilator time, it could moderately reduce the duration of hospital stays in patients with severe COVID-19 infection Tiseo G et al. (2023)[10]. Our findings suggest that similar benefits may be seen in community-managed patients, potentially reducing the overall disease burden and improving patient outcomes.

The data in table 3 show a lower rate of hospitalization among patients treated with Remdesivir (OR: 0.29, 95% CI: 0.09, 0.94), indicating its effectiveness in preventing severe disease progression that requires hospital care. This finding is crucial for public health strategies aiming to minimize hospital strain during pandemic peaks. A study by Chen C et al. (2023)[11] found that early treatment with Remdesivir significantly reduced the risk of more severe respiratory tract infection and subsequent hospitalization.

For table 4, Our study found a lower incidence of side effects in the Remdesivir-treated group compared to those untreated (OR: 0.16, 95% CI: 0.05, 0.45), suggesting a favorable safety profile when used early in community settings. This contrasts with some reports of potential adverse effects, especially in severe cases, and underscores the need for ongoing surveillance and assessment of drug safety in various clinical contexts Hegazy SK et al. (2023)[12]. The safety profile indicated here supports the use of Remdesivir in early stages of disease, potentially expanding its usability outside of hospital settings.

Conclusion

The study has demonstrated significant findings regarding the use of Remdesivir in non-hospitalized patients. Through a comprehensive analysis across various dimensions—disease progression, time to recovery, hospitalization rates, and safety profile—the study presents compelling evidence on the benefits of administering Remdesivir early in the course of COVID-19 infection within community settings.

Firstly, the results indicate a profound impact on reducing disease progression. Patients who received Remdesivir early showed a significantly lower rate of disease progression compared to those who did not receive the drug, as evidenced by a substantial decrease in the odds of progression. This finding underscores the potential of Remdesivir not only in mitigating the severity of the virus but also in preventing the development of conditions that require hospital care.

Secondly, the study highlights that early treatment with Remdesivir can expedite clinical recovery. Patients treated with Remdesivir experienced a faster recovery, suggesting that early intervention can shorten the duration of the illness, thereby reducing the overall burden on both patients and the healthcare system.

Thirdly, an important aspect of pandemic management is reducing hospitalization rates to prevent healthcare overburdening, and our data showed a significant reduction in

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 11, 2024

hospitalizations among patients treated with Remdesivir. This effect could play a critical role in maintaining healthcare capacity and ensuring resources are available for the most severe cases.

Furthermore, the safety profile of Remdesivir was thoroughly evaluated, revealing a lower incidence of side effects among those treated with the drug in community settings. This supports the use of Remdesivir as a safe treatment option in the early stages of COVID-19, aligning with its intended role in early intervention strategies.

In conclusion, this thesis provides robust evidence supporting the strategic use of Remdesivir for early treatment of COVID-19 in community settings. It contributes valuable insights into the potential public health benefits of widespread and early use of antiviral therapies to control the spread of the virus, reduce the severity of the disease, and maintain the integrity of healthcare systems during pandemics. Future policies and healthcare guidelines should consider these findings to optimize the management of COVID-19, particularly in preparing for and mitigating future outbreaks.

Limitations of Study

1. **Retrospective Study Design**: The retrospective nature of the study may limit the ability to establish causality between Remdesivir administration and improved outcomes. Prospective randomized controlled trials are needed to confirm these findings and eliminate potential biases related to retrospective data collection and analysis.
2. **Sample Size**: The study involved a relatively small sample size of 120 participants, which may not provide sufficient power to detect smaller effect sizes or to generalize the findings to a broader population. Larger studies would help to confirm the robustness of the results.
3. **Selection Bias**: As the study population was limited to those treated in community settings, selection bias may influence the outcomes. Patients requiring hospitalization at the onset of symptoms were excluded, potentially skewing results toward those with milder forms of the disease.
4. **Control Group Characteristics**: The absence of a perfectly matched control group (e.g., untreated patients closely matching the treated group in terms of demographic and health characteristics) can affect the validity of the comparisons. The differences in outcomes may be partially attributed to underlying differences between the groups rather than the effect of Remdesivir alone.
5. **Variability in Treatment Regimens**: There may have been variability in how Remdesivir was administered in terms of timing, dosage, and duration, as well as differences in supportive care measures provided to patients. This variability could affect the study's results and makes it difficult to standardize the impact of Remdesivir across the study population.
6. **Reporting and Measurement Bias**: Relying on medical records and self-reports for data collection can introduce errors due to inaccurate or incomplete reporting of clinical outcomes and side effects. This could affect the reliability of the findings regarding both efficacy and safety.
7. **Geographic and Demographic Limitations**: The study was conducted in specific community settings, which may not reflect the diversity of populations globally. Differences in healthcare infrastructure, population demographics, and COVID-19 prevalence could influence the applicability of the results to other regions.

ISSN: 0975-3583,0976-2833 VOL15, ISSUE 11, 2024

8. **Impact of Concurrent Therapies**: During the study period, other therapeutic measures and changes in COVID-19 management strategies could have influenced patient outcomes independently of Remdesivir therapy. The study did not fully control for the use of other medications or therapeutic interventions, which could confound the results.
9. **Duration of Follow-up**: The follow-up period might not have been long enough to capture long-term outcomes and potential late-onset side effects of Remdesivir, limiting the understanding of the full impact of early treatment on disease progression and recovery.

References

1. Blair HA. Remdesivir: a review in COVID-19. Drugs. 2023 Sep;83(13):1215-37.
2. Nhean S, Varela ME, Nguyen YN, Juarez A, Huynh T, Udeh D, Tseng AL. COVID-19: a review of potential treatments (corticosteroids, remdesivir, tocilizumab, bamlanivimab/etesevimab, and casirivimab/imdevimab) and pharmacological considerations. Journal of pharmacy practice. 2023 Apr;36(2):407-17.
3. Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery. 2023 Jun;22(6):449-75.
4. Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID-19. The Cochrane database of systematic reviews. 2023;2023(1).
5. Marx K, Gončarova K, Fedders D, Kalbitz S, Kellner N, Fedders M, Lübbert C. Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany. Infection. 2023 Feb;51(1):97-108.
6. Brown SM, Katz MJ, Ginde AA, Juneja K, Ramchandani M, Schiffer JT, Vaca C, Gottlieb RL, Tian Y, Elboudwarej E, Hill JA. Consistent effects of early remdesivir on symptoms and disease progression across at-risk outpatient subgroups: treatment effect heterogeneity in PINETREE study. Infectious Diseases and Therapy. 2023 Apr;12(4):1189-203.
7. Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Frontiers in immunology. 2023 Jan 26;14:1125246.
8. Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, Lawler PR, Sise ME, Leaf DE. Therapeutic advances in COVID-19. Nature Reviews Nephrology. 2023 Jan;19(1):38-52.
9. Levien TL, Baker DE. Remdesivir. Hospital Pharmacy. 2023 Oct;58(5):420-30.
10. Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, Kalo J, Sponga P, Cesaretti M, Marchetti G, Forniti A. Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: the PISA outpatient clinic experience. Infectious Diseases and Therapy. 2023 Jan;12(1):257-71.
11. Chen C, Fang J, Chen S, Rajaofera MJ, Li X, Wang B, Xia Q. The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: A systematic review and meta-analysis. BMC Infectious Diseases. 2023 Oct 9;23(1):672.
12. Hegazy SK, Tharwat S, Hassan AH. Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients. Open Medicine. 2023 Aug 9;18(1):20230768.